mortality/aging
• mortality during the first 12 hours following 70% hepatectomy is 5.5%
|
Allele Symbol Allele Name Allele ID |
Stat3tm1Xyfu targeted mutation 1, Xin-Yuan Fu MGI:3768531 |
||||||||||||||||||||||||
Summary |
5 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mortality during the first 12 hours following 70% hepatectomy is 5.5%
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• much thinner at age P21, more severe than in mice with wildtype Stat3 allele
|
• severe reduction at age P21, more severe than in mice with wildtype Stat3 allele
|
• severe reduction at age P21, more severe than in mice with wildtype Stat3 allele
|
• severe reduction at age P21, more severe than in mice with wildtype Stat3 allele
|
• much thinner at age P21, more severe than in mice with wildtype Stat3 allele
|
• largely disappeared at age P21, more severe than in mice with wildtype Stat3 allele
|
• much thinner at age P21, more severe than in mice with wildtype Stat3 allele
|
• much thinner at age P21, more severe than in mice with wildtype Stat3 allele
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• mortality during the first 12 hours following a 70% hepatectomy is 35.3% compared to 5.5% in Stat3tm1Xyfu homozygotes
• however, mortality rates after 72 hours are similar
|
• following a 70% hepatectomy or carbon tetrachloride injection, hepatocyte proliferation is less than in Stat3tm1Xyfu homozygotes
• however, liver regeneration following hepatectomy is completed
|
• following carbon tetrachloride injection
|
• following carbon tetrachloride injection
|
• following carbon tetrachloride injection
|
• following carbon tetrachloride injection
|
• following a 70% hepatectomy or carbon tetrachloride injection, hepatocyte proliferation is less than in Stat3tm1Xyfu homozygotes
• however, liver regeneration following hepatectomy is completed
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• after 6 months of age
|
• at 200 days, mice exhibit increased left ventricular chamber size compared with wild-type mice
|
• mild at 6 months
• severe at 9 months
|
• after 6 months of age
|
• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice
|
• at 200 days
|
• after 6 months of age
|
• in the cardiac myocytes of LPS-treated mice
|
• LPS-treated mice exhibit increased myocyte apoptosis and TNF-alpha levels in cardiac myocytes compared with similarly treated wild-type mice
|
• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice
|
• after 6 months of age
|
• after 6 months of age
|
• at 200 days
|
• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice
|
• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• in the cardiac myocytes of LPS-treated mice
|
• LPS-treated mice exhibit increased TNF-alpha levels in cardiac myocytes compared with similarly treated wild-type mice although not as severely as in homozygous mice
|
• severe at 9 months
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 10/22/2024 MGI 6.24 |
|
|